about
Cancer-associated thrombotic microangiopathyThe Father, Son and Cholix Toxin: The Third Member of the DT Group Mono-ADP-Ribosyltransferase Toxin FamilyTowards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infectionCCR9 in cancer: oncogenic role and therapeutic targetingZebrafish Models of Human Leukemia: Technological Advances and Mechanistic InsightsA novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Targeted diphtheria toxin to treat BPDCN.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in micePhase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityDesign and evaluation of a peptide-based immunotoxin for breast cancer therapeutics.Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity.Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis.A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein.Targeted therapies for cutaneous T-cell lymphomas.Immune-based therapies for childhood cancer.Novel therapeutic options for relapsed hairy cell leukemia.Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens.Synergistic immunotoxin-paclitaxel combination against lymphomaDiphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors[EXPRESS]Analgesia by Deletion of Spinal Neurokinin 1 Receptor Expressing Neurons Using a Bioengineered Substance P-Pseudomonas Exotoxin Conjugate.Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.Endosomal escape efficiency of fusogenic B18 and B55 peptides fused with anti-EGFR single chain Fv as estimated by nuclear translocation.Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins.Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells.Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
P2860
Q26738984-20BC8E01-153A-40B1-9DB1-3AB2FC86FB57Q26799321-A5EBAEB6-4635-4F5C-AA20-B17011A00AE1Q27005830-2A4E5266-E2DD-41A2-889F-C52A480B357DQ28066712-AF040F3C-1A99-4A49-80B1-B338478AA533Q28078210-A7CE7190-01E1-4608-8154-AF958B4DFDBDQ33758660-59F25301-9A0B-4365-A887-0A04E57B2F9EQ33917153-1913C00D-B2D4-4D60-9BA0-2CFEFFD8AC2BQ35070412-80578BC6-90F9-4C95-A494-86D408BA575AQ35180101-6C765C94-087C-4A79-8BD1-8A0156125693Q35189855-BF8A627F-400A-4EBC-8977-73DADE75F4B2Q35244073-0A4C5D39-6FD5-4DEB-93C5-D0686590D0EBQ35542237-B8D1A3E2-929A-4072-9009-B9FB5FE6389BQ35845907-9B6967BE-7A26-48D8-A88F-52F44528ECB5Q36217155-B7D3C87C-960B-415A-B4DB-587D615E9703Q36917916-D4A2173A-5686-437C-805F-B204DEA7F90DQ37281460-E3DB4303-8563-473F-BB98-988BFF300239Q37367958-A3BDBC8A-001D-4D75-B398-1EA72AF326E3Q37370563-6525EE8E-F75D-4399-8E6B-0D6F89FDC550Q37376200-713DEB89-F3BC-482A-B416-976F86258BBCQ37630372-265566AA-FE64-471D-8233-59D487170072Q38229634-36BC3F67-41FE-4BD8-84C6-29B6963021D5Q38263108-8C5A4280-55BC-46BF-BFCA-BCC54DCDB9F6Q38308974-47ADEAF8-4A7A-474E-A972-D85C783F2F17Q38680881-954897AA-B86B-4ED1-8440-AB70A9A0BB6EQ38700209-795A5D88-500A-4C13-8ACE-663703EDE581Q38910559-0DC3BBF2-F8CE-4A80-86D4-CC50CC1D801AQ38936986-26702636-9DB7-4367-B547-E8AC4CD733EFQ39016197-3CC34274-EFC4-4855-BB4E-2550CA43D284Q39338052-C9C0F3BC-E8E6-44ED-ADCF-D5A4DD50CF55Q39823855-55A24CD4-DD2F-4165-98B4-C70BF9899140Q41008443-BC871BE7-E05A-414D-9048-539249646105Q41127909-9E12E0B5-8E65-4FE1-9EB1-5975BFCE89C2Q41544495-33D04125-9167-496F-8CA1-B0B6366E61CBQ41637417-8159115C-3933-4B3D-9A63-74CAD9B3AFE1Q41788803-C7014D2E-A828-4467-8B3B-017F9E0F6447Q42293412-773528EE-6A38-4714-A934-2B3B70B55377Q42327813-2EBE388D-34A5-4A0D-8003-2E9A87FD9139Q46385489-A35D36DA-E930-4B60-BB0B-586943F22DCCQ49539698-1EAE52CC-EDB0-43E7-A41E-EFB1D17A345DQ50063870-1FEA9AF3-35CB-47AC-895E-DAC699A54D2B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotoxins for leukemia.
@en
Immunotoxins for leukemia.
@nl
type
label
Immunotoxins for leukemia.
@en
Immunotoxins for leukemia.
@nl
prefLabel
Immunotoxins for leukemia.
@en
Immunotoxins for leukemia.
@nl
P2093
P2860
P1433
P1476
Immunotoxins for leukemia.
@en
P2093
Alan S Wayne
David J Fitzgerald
Ira Pastan
Robert J Kreitman
P2860
P304
P356
10.1182/BLOOD-2014-01-492256
P407
P577
2014-02-27T00:00:00Z